AMENDMENTS TO THE CLAIMS

1. (Currently amended) ~~Compounds of the general~~ A compound of formula I



Formula I

wherein

R^1 represents the groups



whereby in these groups R^5 is hydrogen, lower alkyl with 1 to 4 carbon atoms, or the group



wherein

R^8 represents, lower alkyloxy, lower alkylamino, or lower alkyl with 1 to 4 carbon atoms;

R^9 represents, lower alkyl with 1 to 4 carbon atoms;

R^8 and R^9 together form a 5- or 6- membered heterocyclic ring containing one to two hetero atoms which can be the same or different and are oxygen or nitrogen;

R^6 represent hydrogen, halogen, nitro, or lower alkyloxy;

R^7 represents hydrogen;

R^2 and R^3 independently represent hydrogen, lower alkyl with 1 to 3 carbon atoms, or together a lower alkylene group with 1 to 3 carbon atoms bridging the oxygen atoms and forming a five, six or seven membered ring;

R^4 represents hydrogen

and pharmaceutically acceptable salts thereof.

2. (Currently amended) ~~Compounds of the general~~ A compound of formula I'



Formula I'

wherein

R^1 represents the groups



whereby in these groups R^5 is hydrogen, lower alkyl with 1 to 4 carbon atoms, or the group



wherein

R^8 represents, lower alkyloxy, or lower alkyl with 1 to 4 carbon atoms;

R^9 represents, lower alkyl with 1 to 4 carbon atoms;

R^8 and R^9 together form a 5- or 6- membered heterocyclic ring containing one to two hetero atoms which can be the same or different and are oxygen or nitrogen;

R^6 represent hydrogen, halogen, nitro, or lower alkyloxy;

R^7 represents hydrogen;

R^2 and R^3 independently represent hydrogen, lower alkyl with 1 to 3 carbon atoms, or together a lower alkylene group with 1 to 3 carbon atoms bridging the oxygen atoms and forming a five, six or seven membered ring;

R^4 represents hydrogen;

and pharmaceutically acceptable salts thereof.

3. (Currently amended) ~~Compounds of the general~~ A compound of formula II



Formula II

wherein

R^2 and R^3 represent methyl;

R^4 represents hydrogen;

R^5 and R^6 are as defined in formula I;

R^7 represents hydrogen;

and pharmaceutically acceptable salts thereof.

4. (Currently amended) ~~Compounds of the general~~ A compound of formula III



Formula III

wherein

R^2 and R^3 represent methyl;

R^4 represents hydrogen;

R^5 and R^6 are as defined in formula I;

R^7 represents hydrogen;

and pharmaceutically acceptable salts thereof.

5. (Currently amended) ~~Compounds of the general~~ A compound of formula IV



Formula IV

wherein

R^2 and R^3 represent methyl;

R^4 represents hydrogen;

R^5 and R^6 are as defined in formula I;

R^7 represents hydrogen;

and pharmaceutically acceptable salts thereof.

6. (Currently amended) ~~Compounds~~ The compound of claim 1 selected from the group consisting of:

5-[6,7-Dimethoxy-2-(7-methoxy-1H-indol-3-ylmethyl)-benzofuran-4-ylmethyl]-pyrimidine-2,4-diamine;

5-[6,7-Dimethoxy-2-(5-methoxy-1H-indol-3-ylmethyl)-benzofuran-4-ylmethyl]-pyrimidine-2,4-diamine;

5-[2-(1H-Indol-3-ylmethyl)-6,7-dimethoxy-benzofuran-4-ylmethyl]-pyrimidine-2,4-diamine;

5-[6,7-Dimethoxy-2-(2-methyl-1H-indol-3-ylmethyl)-benzofuran-4-ylmethyl]-pyrimidine-2,4-diamine;

5-[2-(6-Fluoro-1H-indol-3-ylmethyl)-6,7-dimethoxy-benzofuran-4-ylmethyl]-pyrimidine-2,4-diamine;

{3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indol-2-yl}-morpholin-4-yl-methanone;

3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indole-2-carboxylic acid dimethylamide;

5-[6,7-Dimethoxy-2-(5-nitro-1H-indol-3-ylmethyl)-benzofuran-4-ylmethyl]-pyrimidine-2,4-diamine;

{3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indol-2-yl}-pyrrolidin-1-yl-methanone;

3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-5-methoxy-1H-indole-2-carboxylic acid dimethylamide;

3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indole-2-carboxylic acid methoxy-methyl-amide;

5-Chloro-3-[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indole-2-carboxylic acid dimethylamide;

3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-5-fluoro-1H-indole-2-carboxylic acid dimethylamide;

5-Chloro-3-[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indole-2-carboxylic acid methoxy-methyl-amide;

3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indole-2-carboxylic acid N,N'-dimethyl-hydrazide;

3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-5-fluoro-1H-indole-2-carboxylic acid methoxy-methyl-amide;

and pharmaceutically acceptable salts thereof.

7. (Currently amended) ~~Intermediates of the general~~ An intermediate compound of formula XI and XII[[.]]



XI



XII

wherein R^2, R^3, R^4, R^5 and R^6 have the meaning given in formula I in claim 1 and 2.

8. (Currently amended) ~~Pharmaceutical compositions~~ A pharmaceutical composition comprising one or more compounds of ~~any one of claims 1 to 6~~ claim 1 and ~~usual~~ a pharmaceutically acceptable inert carrier ~~materials~~ material.

9. (Cancelled).

10. (Cancelled).

11. (Cancelled).

12. (Cancelled).

13. (Cancelled).

14. (Cancelled).

15. (Cancelled).

16. (Currently amended) A process for the manufacture of a pharmaceutical ~~compositions~~ composition containing one or more compounds as claimed in ~~any one of claims 1 to 6~~ claim 1 as active ingredients, which process comprises mixing one or more active ingredients with a pharmaceutically acceptable inert carrier ~~materials and adjuvants in a manner known per se~~ material and/or an adjuvant.

17. (Cancelled).

18. (New) A process for the manufacture of a pharmaceutical composition comprising one or more compounds as claimed in claim 6 as active ingredients, which process comprises mixing one or more active ingredients with a pharmaceutically acceptable inert carrier material and/or an adjuvant.

19. (New) A pharmaceutical composition comprising one or more compounds of claim 6 and a pharmaceutically acceptable inert carrier material.

20. (New) A method for treating a bacterial infection comprising administering to a subject in need thereof an effective amount of the compound of claim 1.

21. (New) The method of claim 20, wherein the bacterial infection is caused by a Gram positive pathogen or Gram negative pathogen.

22. (New) A method for treating a bacterial infection comprising administering to a subject in need thereof an effective mount of the compound of claim 6.

23. (New) The method of claim 22, wherein the bacterial infection is caused by a Gram positive pathogen or Gram negative pathogen.